Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 6;12(1):e055351.
doi: 10.1136/bmjopen-2021-055351.

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Ariadna Colomer-Carbonell  1   2 , Juan P Sanabria-Mazo  1   2 , Halbert Hernández-Negrín  2   3 , Xavier Borràs  2 , Carlos Suso-Ribera  4   5 , Azucena García-Palacios  4   5 , Jordi Muchart  6 , Josep Munuera  6 , Francesco D'Amico  7 , Michael Maes  8 , Jarred W Younger  9 , Albert Feliu-Soler  10 , Antoni Rozadilla-Sacanell  11 , Juan V Luciano  12   10
Affiliations

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Ariadna Colomer-Carbonell et al. BMJ Open. .

Abstract

Introduction: There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility and neurobiological effects of LDN for reducing pain in patients with FMS, with a 1-year follow-up.

Methods and analysis: A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (eg, pain intensity, fatigue and sleep disturbance), and side effects via ecological momentary assessment through the Pain Monitor app during the first 3 months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with MRI at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitisation. Inflammatory biomarkers in serum will also be measured.

Ethics and dissemination: This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and community engagement activities.

Trial registration number: NCT04739995.

Keywords: clinical trials; health economics; pain management.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow chart of the INNOVA study based on the Consolidated Standards of Reporting Trials guidelines. FMS, fibromyalgia syndrome; ITT, intention-to-treat; LDN, low-dose naltrexone.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Häuser W, Ablin J, Fitzcharles M-A, et al. . Fibromyalgia. Nat Rev Dis Primers 2015;1:15022. 10.1038/nrdp.2015.22 - DOI - PubMed
    1. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed 2007;78:88–95. - PubMed
    1. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013;17:356. 10.1007/s11916-013-0356-5 - DOI - PubMed
    1. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. Curr Opin Investig Drugs 2010;11:16–18. - PubMed
    1. Nüesch E, Häuser W, Bernardy K, et al. . Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013;72:955–62. 10.1136/annrheumdis-2011-201249 - DOI - PubMed

Publication types

Associated data